Ivermectin 3 mg + Albendazole 200 mg is a combination antiparasitic used for intestinal worm infestations and broader deworming programs, offering enhanced activity against Trichuris and coverage for multiple soil-transmitted helminths compared with single agents in several evaluations. Ivermectin targets invertebrate glutamate-gated chloride channels, leading to paralysis of parasites through channel opening and sustained chloride influx. Albendazole impairs parasite survival by inhibiting β-tubulin–mediated microtubule polymerization and glucose uptake, depleting energy reserves and causing death. This co-formulation is recognized in programmatic guidance for helminth control and mass drug administration in suitable populations.